ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel et al. · Journal of Clinical Oncology · 2008 · 3.2K citations

Medicine, Oncology, Pharmacology +16

SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD

Nadia Howlader · Medical Entomology and Zoology · 2011 · 2.4K citations

Medicine, Biostatistics, Oncology +11

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

Lisa M. McShane, Douglas G. Altman, Willi Sauerbrei et al. · JNCI Journal of the National Cancer Institute · 2005 · 2.1K citations · Full text

Medicine, Biostatistics, Oncology +16

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Ken A. Olaussen, Ariane Dunant, Pierre Fouret et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text

Medicine, Molecular Biology, Oncology +16

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Journal of Clinical Oncology · 2009 · 1.5K citations

Medicine, Oncology, Pharmacology +13